A Phase 3 interventional study of Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ and Comparator: placebo (concomitant-vaccine matched) in Herpes Zoster and Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-12.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Herpes Zoster by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Herpes Zoster · Merck & Co., Inc.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, this one is the 10th largest by enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2007, is one of 14 in phase 3, and was the 5th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →None of the 27 studies in Herpes Zoster by Merck & Co., Inc is open now. The open studies under Herpes Zoster, anywhere →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 1995; this study’s year is marked. 6 started in 2007.
This study's enrollment of 473 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 354 across the 25 interventional studies, 756,616 across the 2 observational. Of the 26 that completed or were terminated, 24 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Herpes Zoster by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Zoster Vaccine Live and Pneumococcal Vaccine, polyvalent are as well tolerated and immunogenic when the vaccines are given together (in different body sites), as when they are given alone, in adults 60 years of age and older.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Comparator
Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ · Biological: Comparator: placebo (concomitant-vaccine matched)
vaccine
Biological: Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ · Biological: Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23
0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
Also known as: ZOSTAVAX™
Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
Also known as: PNEUMOVAX™ 23
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay
Time frame: 4 weeks postvaccination
Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.
GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23. gpELISA = glycoprotein enzyme-linked immunosorbent assay.
Time frame: Four weeks postvaccination
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.
GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
Time frame: Four weeks postvaccination
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.
GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
Time frame: Four weeks postvaccination
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.
GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
Time frame: Four weeks postvaccination
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.
GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
Time frame: Four weeks postvaccination
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.
Time frame: Eight weeks postvaccination
Phase III First subject enrolled on 18-Jun-2007. Last subject enrolled on 05-Dec-2007. The last subject's last visit was 11-Feb-2008. The study was conducted at 18 study centers throughout Canada, Australia, and Europe.
| Milestone | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Started | 236 | 237 |
| Completed | 234 | 230 |
| Not completed | 2 | 7 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 4 |
GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay
| gpELISA units*/mL | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination | 448.5 (400.3 to 502.4) | 371.6 (328.7 to 420.0) |
All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.
| Participants | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Injection site AEs | 141 | 136 |
| Systemic AEs | 74 | 70 |
| Serious AEs | 4 | 2 |
| Varicella-like Rash | 3 | 2 |
| Zoster-like Rash | 1 | 1 |
GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23. gpELISA = glycoprotein enzyme-linked immunosorbent assay.
| gpELISA units/mL | Concomitant Group |
|---|---|
| Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination. | 1.9 (1.7 to 2.1) |
GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
| micrograms/mL | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination. | 1.2 (1.1 to 1.4) | 1.1 (1.0 to 1.2) |
GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
| micrograms/mL | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination. | 26.5 (22.9 to 30.8) | 25.7 (21.8 to 30.3) |
GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
| micrograms/mL | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination. | 10.5 (8.7 to 12.6) | 10.5 (8.7 to 12.7) |
GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.
| micrograms/mL | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination. | 2.8 (2.3 to 3.3) | 2.5 (2.1 to 3.0) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nonconcomitant Group | — | — | — |
| Concomitant Group | — | — | — |
| Event | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/236 | 1/235 |
| VertigoEar and labyrinth disorders | 0/236 | 1/235 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/236 | 0/235 |
| Non-Hodgkin's LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/236 | 0/235 |
| HaematomaVascular disorders | 1/236 | 0/235 |
| DiverticulitisInfections and infestations | 1/236 | 0/235 |
| Global amnesiaNervous system disorders | 1/236 | 0/235 |
| Event | Nonconcomitant Group | Concomitant Group |
|---|---|---|
| Pain (PNEUMOVAX™ 23 injection site)General disorders | 82/236 | 95/235 |
| Pain (ZOSTAVAX™ injection site)General disorders | 68/236 | 74/235 |
| Erythema (ZOSTAVAX™ injection site)General disorders | 70/236 | 72/235 |
| Swelling (ZOSTAVAX™ injection site)General disorders | 63/236 | 67/235 |
| Swelling (PNEUMOVAX™ 23 injection site)General disorders | 30/236 | 49/235 |
| Erythema (PNEUMOVAX™ 23 injection site)General disorders | 30/236 | 46/235 |
| Pain (Placebo injection site)General disorders | 21/236 | 8/235 |
| HeadacheNervous system disorders | 4/236 | 13/235 |
| Pruritus (ZOSTAVAX™ injection site)General disorders | 8/236 | 11/235 |
| NasopharyngitisInfections and infestations | 5/236 | 9/235 |
| Age, Continuous(years) | Nonconcomitant Group | Concomitant Group | Total |
|---|---|---|---|
| Mean | 66.0 ± 5.6 | 66.3 ± 5.6 | 66.2 ± 5.6 |
| Sex: Female, Male(Participants) | Nonconcomitant Group | Concomitant Group | Total |
|---|---|---|---|
| Female | 135 | 138 | 273 |
| Male | 101 | 97 | 198 |
| Race/Ethnicity, Customized(participants) | Nonconcomitant Group | Concomitant Group | Total |
|---|---|---|---|
| Asian | 1 | 1 | 2 |
| Black or African American | 0 | 1 | 1 |
| White | 235 | 233 | 468 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Jun 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2009, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 23-valent pneumococcal capsular polysaccharide vaccine